Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zeneca's Seroquel reduction in schizophrenia symptoms similar to haloperidol.

Executive Summary

ZENECA SEROQUEL SCHIZOPHRENIA SYMPTOM IMPROVEMENT SIMILAR TO HALOPERIDOL, according to results from Zeneca's North American Phase III trial of the antipsychotic agent reported at the American College of Neuropsychopharmacology annual meeting in Puerto Rico. Seroquel (ICI 204,636) 300 mg per day decreased symptoms as assessed by the Brief Psychiatric Rating Scale by 8.6 points compared to 7.6 points for haloperidol at the end of six weeks. The difference was not statistically significant.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS027439

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel